The market space of biopharmaceutical equipment in China is vast, and the absence of middle and high-end equipment is prominent

[pharmaceutical network market analysis] according to the report released at the 2019 China Biotechnology Innovation Conference, in 2018, the market size of China's biomedical industry has exceeded 350 billion yuan, and 9 independently developed class 1 new drugs have been approved for listing These data fully show that the level of biomedicine in China is constantly improving The industry said that with the rapid rise of China's biomedical industry, the demand for pharmaceutical equipment is also expanding China's biopharmaceutical equipment market has a broad space, and the absence of middle and high-end products is prominent (photo source: pharmaceutical network) China's biopharmaceutical market is growing rapidly, and the demand for pharmaceutical equipment is increasing Biopharmaceutical industry is one of the important pillar industries of modern pharmaceutical industry Nowadays, with the launch of a series of national policies, domestic pharmaceutical enterprises are transforming from "generic strategy" to "innovative drug strategy" Some pharmaceutical enterprises pay attention to new drug research and development gradually appear in China, and the bull stocks in the field of biopharmaceutical industry are constantly emerging, such as Changchun hi tech, the leader of biopharmaceutical industry, which has doubled 28 times in 10 years , high growth clinical cro leader tag medicine, etc., whose share price has more than 20 times in the past 9 years With the country's increasing emphasis on the research and development of innovative drugs, the market demand for biomedicine will continue to grow, and more bull stocks will be generated in the biomedical field in the future Nowadays, the biomedical industry has become a national strategic emerging industry, and its market scale is growing at a relatively fast speed According to some data, the annual compound growth rate of China's biomedical market scale from 2014 to 2018 is 21.9%, far higher than the growth rate of the pharmaceutical market It is predicted that by 2021, the market scale of China's biomedical industry will reach 326.9 billion yuan The rapid development of China's biomedical industry is good news for patients, as well as for the upstream pharmaceutical equipment industry According to the industry, with the vigorous development of biomedical industry, the market demand for biopharmaceutical equipment in China will further expand, and the biopharmaceutical equipment industry will usher in a broad market space The author has learned that in recent years, with the increasing market demand, pharmaceutical equipment enterprises in China are also making efforts, and biopharmaceutical equipment products and technologies are emerging in an endless stream, such as Tianshui Huayuan, which produces bio microwave extraction equipment under this opportunity; in addition, the bio extraction equipment produced by a pharmaceutical machine enterprise in response to the market demand has made great improvements in energy saving and efficiency "Through the full closed cycle extraction and concentration, the biological extraction equipment can save energy by 0.3-0.5 times; in addition, the equipment can reduce the solvent by 0.5-1 times according to different drugs, increase the feeding amount by 30% - 60%, and increase the paste yield by more than 10%." The head of the enterprise introduced The market space of biopharmaceutical equipment is vast, but pharmaceutical enterprises still rely on the rapid development of imported equipment biopharmaceutical industry, which makes China's biopharmaceutical equipment industry usher in huge market opportunities, and some new technologies and equipment begin to emerge The birth of new biopharmaceutical equipment and technology is of great significance to the development and quality improvement of biopharmaceutical industry in China However, it is worth mentioning that at present, the high-end market of biopharmaceutical equipment in China is seriously absent, the overall innovation ability of the industry is still weak, the product quality is also uneven, the trust of pharmaceutical enterprises in domestic biopharmaceutical equipment is low, and many enterprises are relatively dependent on imported equipment For example, the head of a domestic biopharmaceutical enterprise said in an interview with the media that 95% of the company's biopharmaceutical equipment is imported The production process of biomedicine is more complicated than that of traditional Chinese medicine and chemical medicine "Traditional Chinese medicine is processed, chemical medicine is synthesized by small molecules, and biological medicine grows from living cells." In the production process of biomedicine, the number of dust particles per cubic meter (air) can not exceed 20 On the one hand, the requirements for cleanliness are higher, on the other hand, the requirements for aseptic production are higher It is understood that biopharmaceuticals have very strict requirements for pharmaceutical environment, and they have higher requirements for sterile and pollution-free conditions of pharmaceutical equipment, so they also have higher requirements for structural parameters, process parameters, control methods of equipment But in these aspects, there is still a big gap between domestic equipment and foreign advanced equipment For example, the production equipment used in traditional biopharmaceutical production process is stainless steel material, which not only makes the production and installation of the equipment take a long time, but also brings heavy work of cleaning, sterilization and disinfection for pharmaceutical enterprises The key is the risk of cross contamination In response to this, a foreign enterprise has launched a one-time technology, which has the ability to provide users of the biopharmaceutical industry with complete production process technology and required equipment In recent years, with the rapid rise of domestic biomedical industry, many multinational pharmaceutical equipment enterprises have successively arranged the market in China, and are trusted by domestic enterprises by virtue of their technological advantages Facing the market environment of "before there are wolves, after there are tigers", analysts said that China's biopharmaceutical equipment enterprises should seize the market opportunities given by the national policy support, continuously carry out technological innovation, stabilize product performance, improve product technology and quality, so as to win the market with high cost-effective products.